Literature DB >> 32702080

Uptake of Infliximab Biosimilars Among the Medicare Population.

Alice J Chen1,2, Laura Gascue1, Rocio Ribero1, Karen Van Nuys1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32702080      PMCID： PMC7372498          DOI： 10.1001/jamainternmed.2020.3188

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

1.  Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.

Authors:  Steven Kozlowski; Noy Birger; Stephaeno Brereton; Stephen J McKean; Michael Wernecke; Leah Christl; Jeffrey A Kelman
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

2.  Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.

Authors:  Emily Leonard; Michael Wascovich; Sonia Oskouei; Paula Gurz; Delesha Carpenter
Journal:  J Manag Care Spec Pharm       Date:  2019-01

3.  Provider differences in biosimilar uptake in the filgrastim market.

Authors:  Alice J Chen; Rocio Ribero; Karen Van Nuys
Journal:  Am J Manag Care       Date:  2020-05       Impact factor: 3.247

4.  Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.

Authors:  Hillel Cohen; Donna Beydoun; David Chien; Tracy Lessor; Dorothy McCabe; Michael Muenzberg; Robert Popovian; Jonathan Uy
Journal:  Adv Ther       Date:  2016-10-31       Impact factor: 3.845
  4 in total
  4 in total

Review 1.  Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.

Authors:  Hala Najeeb; Farah Yasmin; Salim Surani
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

2.  Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.

Authors:  Emma Boswell Dean; Phyllis Johnson; Amelia M Bond
Journal:  JAMA Netw Open       Date:  2021-01-04

3.  Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.

Authors:  Sean R Dickson; Tyler Kent
Journal:  JAMA Netw Open       Date:  2021-11-01

4.  Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.

Authors:  S M Qasim Hussaini; Arjun Gupta; Kelly E Anderson; Jeromie M Ballreich; Lauren Hersch Nicholas; G Caleb Alexander
Journal:  JAMA Netw Open       Date:  2022-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.